About this trial
The uterine fibroids are the most common benign tumors found in the female reproductive system. Uterine fibroids commonly cause heavy menstrual periods. The prevalence of uterine fibroids is significantly affecting up to 70-80% of women by the age of 50, with an inconsistent impact on women of African origin. Carbitocin is a synthetic analogue of oxytocin which has a longer half-life than oxytocin. A Cochrane review and meta-analysis studies found that carbitocin reduced the use of additional uterotonics and transfusion. However, few of these studies was done during myomectomy.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
All consented women booked for myomectomy.
No know allergy to Cabetocin.
Billed for open abdominal myomectomy.
Disqualifiers
Declined consent
Allergy to Cabetocin
Planned for additional uterotonic
Prior history of thromboembolism,
Trial design
Parallel
Treatments tested in this trial
Carbetocin
DrugCarbitocin is an oxytocid with longer half life
Treatment groups
Trial outcomes
Primary outcomes
Haemoglobin Change
Pre and Post operative Haemoglobin will be compared
Secondary outcomes
Transfusion rates
The number of units of blood used
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: